Bain Capital’s Bet Against Romney

As debate season heats up, we had an interesting takeaway from the first 2012 Presidential debate yesterday. Obama failed to mention anything about Romney’s old firm, Bain Capital. That is not going to stop us from mentioning it—in the issues that Romney and Obama did discuss, Romney continued to take the hardline that he would repeal Obamacare if elected.

As mentioned, the fact that Obama failed to discuss anything Bain-related made us think about the firm even more. In looking over Bain’s long/short public equity fund, Brookside Capital, we noticed the company had almost 10% of their 2Q 13F portfolio invested in biopharmaceutical companies—see all of Bain’s Brookside Capital holdings.

David Shaw

With Romney noting that he plans to repeal Obamacare, we believe that Bain might be betting on a Romney presidential win, but not on Romney following through with an Obamacare repeal. While most of the talk surrounding Healthcare Reform and Obamacare has been about the managed healthcare companies, such as WellPoint and Aetna, we believe there will be other impacts for pharmaceutical companies. Of course, big pharma companies, like Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE), will see increased demand due to the spike in the number of individuals with healthcare. However, we believe there will also be an increase in drug development, presenting the case that Obamacare would be beneficial for biopharmaceutical companies.

Worth noting is that not everyone agrees that Obamacare would be positive for the largest pharmaceutical company in the world, Pfizer included. The overhanging issue for Pfizer is that if Obamacare stands, the company will be affected by the ‘donut hole’ that the Medicare plan would produce. Pfizer would be required to be make a series of payments by 2020, which would likely force it to raise prices, therefore impacting the company’s margins. Despite this risk, it is still numero uno of the ten most popular healthcare stocks among hedge funds.

We believe that more healthcare coverage from Obamacare should begat a greater need for preventative care and prescription drugs. As well, the healthcare reform law establishes an FDA infrastructure that governs biosimilar drug approvals, which grants a 12-year exclusivity to branded drug makers. Two of the four holdings by Brookside have a biosimilar drug portfolio.

Brookside owned 5.6 million shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) at the end of 2Q, which was 3.5% of their 13F portfolio. Vertex is in the business of developing and manufacturing small molecule drugs for the treatment of serious diseases. S&P recently increased its price target to $67 based on an enhanced pipeline. Vertex is by far the biggest biopharma company of Bain’s four, having a market cap of over $12 billion, versus all the others at sub-$2 billion. For fund investors, D.E. Shaw was the only fund owning more shares of Vertex at the end of 2Q than Brookside, with over 4 million. However, a negative for the company has been the recent number of insider sales, in the range of $55-$60, with the stock currently trading around $60 a share.

Amarin Corporation PLC (NASDAQ:AMRN) is a late-stage biopharmaceutical company with a focus in the treatment of cardiovascular disease. The company was a new position for Brookside in 2Q. Wedbush recently downgraded Amarin, citing that the speculation premium might be overdone. The company is up 60% year to date on the thought that Amarin could be a prime takeover target. Insiders may be fearful of no deal as well, with a number of insiders selling of late.

MAP Pharmaceuticals Inc. (NASDAQ:MAPP) is a development-stage company, with a current focus on orally inhaled migraine therapy. Brookside owned 3 million shares at the end of June, and held their position steady throughout the quarter. In August the company announced plans to sell shares of stock to raise money for development of its key drug, Levadex. MAP has put its sole focus on the migraine market, but the market appears to be ripe. Statistics show that nearly 30 million people suffer from migraines in the U.S. and over 113 million days of work are lost. Brookside is by far the largest fund owner, but notable investor Ken Griffin is also invested in the stock.

Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Brookside had 3% of its 13F invested in Idenix and was the firm’s eleventh largest holding. Merrill Lynch recently downgraded the company based on limited hope that Idenix can convince the FDA to allow further clinical testing of its drug for hepatitis C. The company received a letter from the FDA that a clinical hold had been placed on testing the drug. Idenix is one of Seth Klarman’s top picks. Klarman’s Baupost Group owns nearly as many shares as Brookside, both owning over 10 million shares each, collectively owning over 16% of the company.

Given the nature of the operations that these biopharmaceutical companies partake in, their P/E ratios trade in wide ranges. MAP and Amarin have incalculable P/E ratios, where IDEX trades at a 17 P/E and Vertex at 31X. Although Vertex trades at the highest P/E, we see it as the most stable and least risky stock. However, all the companies should be considered speculative. For a longer look at Brookside Capital’s 13F portfolio, continue reading at Insider Monkey.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!